You need to run a preclinical proof-of-concept study in our field of expertise — but you don’t have the in-house know-how or the resources to make it happen. With 25+ years of experience, 200+ studies conducted, and 4 IND-enabling programs completed in the past 4 years, Pelvipharm helps pharmaceutical and biotech companies demonstrate the efficacy of their drug candidates using the most relevant translational preclinical models. If your program targets functional urology, sexual medicine, or women’s health, we can support you from concept to data-driven decisions — efficiently and confidentially. 👉 Reach out today and book a meeting ! (First come, first served basis.)
Looking for a particular PELVIPHARM employee's phone or email?
The PELVIPHARM annual revenue was $5 million in 2026.
Delphine Behr-Roussel is the CEO and CSO of PELVIPHARM.
9 people are employed at PELVIPHARM.
PELVIPHARM is based in Montigny-le-Bretonneux, Île-de-France.
The NAICS codes for PELVIPHARM are [5417, 54, 541, 541713, 54171].
The SIC codes for PELVIPHARM are [87, 873].